Diabetic renal disease: who to refer, when to refer

Sign In to gain access to subscriptions and/or personal tools.

This Article

	Full Text (PDF)
	Alert me when this article is cited
	Alert me if a correction is posted
	Citation Map

Services

	Email this article to a friend
	Similar articles in this journal
	Alert me to new issues of the journal
	Add to Saved Citations
	Download to citation manager
	Request Permissions
	Request Reprints
	Add to My Marked Citations

Citing Articles

	Citing Articles via Google Scholar
	Citing Articles via Scopus

Google Scholar

	Articles by Page, M.
	Search for Related Content

Social Bookmarking

	What's this?

Mike Page

Selly Oak Hospital, Raddlebarn Road, Selly Oak, Birmingham, B29 6JD, UK, helen.roberts{at}university-b.wmids.nhs.uk

References

Laffel LM, McGill JB, Gans DJ The beneficial effect of angiotensin converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. Am J Med 1995; 99:497-504.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

Mogensen CE, Neldam S., Tikkanen I. et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000;321:1440-4.[Abstract/Free Full Text]

Parving HH, Lehnert H., Brochner-Mortensen J. et al. The effect of irbesartan on the development of diabetic nephropathy in patients with Type 2 diabetes. N Engl J Med 2001;345:871-8.

Parving HH, Rossing P., Hommel E. et al. Angiotensin-converting enzyme in diabetic nephropathy: ten years' experience. Am J Kidney Dis 1995; 26:99-107.[Web of Science][Medline] [Order article via Infotrieve]

Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. N Engl J Med 2001;345:851-60.[Abstract/Free Full Text]

Brenner BM, Cooper ME, de Zeeuw D. et al. Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.[Abstract/Free Full Text]

Dyer P., Barnett A. Assessing the benefits of microalbuminuria screening. Prescriber 1998;9.12:79-84.

Trowbridge S., Kerr D., Cavan DA Microalbuminuria screening in Type 2 diabetes - why bother? Diabet Med 1999;16(suppl 1):59.

Borch-Johnsen K. The costs of nephropathy in Type 2 diabetes. Pharmacoeconomics 1995;8(suppl 1):40-5.[Medline] [Order article via Infotrieve]

Kiberd BA, Jindal KK Should all Pima Indians with Type 2 diabetes mellitus be prescribed routine angiotensin converting enzyme inhibition therapy to prevent renal failure? Mayo Clin Proc 1999;74:559-64.[Abstract]

Warram JH, Rich SS, Krolewski AS Epidemiology and genetics of diabetes mellitus. In: Kahn CR, Weir GC, eds. Joslin's Diabetes Mellitus. Philadelphia: Lea & Febiger 1994:201-15.

Earle KK, Porter KA, Ostberg J. et al. Variation in the progression of diabetic nephropathy according to racial origin. Nephrol Dial Transplant 2001;16:286-90.[Abstract/Free Full Text]

Valmadrid CT, Klein R., Moss SE et al. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Int Med 2000;160:1093-100.[Abstract/Free Full Text]

Gerstein HC, Mann JF, Yi Q. et al. Albuminuria and risk of cardiovascular events, death and heart failure in diabetic and non-diabetic individuals. JAMA 2001;286:421-6.[Abstract/Free Full Text]

Renal Association. Treatment of Adult Patients with Renal Failure 2nd Edition, November 1997.

Valabhji J., Robinson S., Poulter C. et al. Prevalence of renal artery stenosis in subjects with Type 2 diabetes and coexistent hypertension. Diabetes Care 2000;23:539-43.[Abstract]